Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size
- 18 April 2007
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (3) , 328-334
- https://doi.org/10.1111/j.1365-2125.2007.02894.x
Abstract
For optimal efficacy, antiasthma drugs should be delivered to the desired region in the airways. To date, the optimal particle size for steroids in adults is not known. The aim of the study was to evaluate the pulmonary bioavailability for inhaled beclomethasone dipropionate (BDP) aerosols of different particle sizes. In a randomized single-blind crossover trial, 10 mild asthmatic patients inhaled monodisperse BDP aerosols with mass median aerodynamic diameters (MMADs) of 1.5, 2.5 and 4.5 microm. Gastrointestinal absorption was blocked by activated charcoal. Plasma concentrations of 17-beclomethasone monopropionate (17-BMP) were measured by liquid chromatography plus mass spectrometry. Aerosols with MMADs of 1.5 microm, 2.5 microm, and 4.5 microm gave mean maximum concentrations (C(max)) of 17-BMP of 475 pg ml(-1), 1300 pg ml(-1), and 1161 pg ml(-1), respectively. The area under the curve (AUC) values of 17-BMP for MMADs of 1.5 microm, 2.5 microm, and 4.5 microm were 825 pg ml(-1) h, 2629 pg ml(-1) h, and 2276 pg ml(-1) h, respectively. The mean terminal half-time of 17-BMP for all three aerosol sizes was around 1.5 h. Monodisperse BDP aerosols with a MMAD of 1.5 microm gave two-three fold lower values for C(max) and AUC than those with MMADs of 2.5 and 4.5 microm.Keywords
This publication has 30 references indexed in Scilit:
- Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in childrenPediatric Pulmonology, 2003
- Targeting Delivery of Aerosols to Different Lung RegionsJournal of Aerosol Medicine, 2002
- Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in manBritish Journal of Clinical Pharmacology, 2001
- Why Particle Size Should Affect Clinical Response to Inhaled TherapyJournal of Aerosol Medicine, 2001
- Adrenal Effects and Pharmacokinetics of CFC-free Beclomethasone Dipropionate: a 14-Day Dose-Response StudyJournal of Pharmacy and Pharmacology, 1999
- Respiratory pathophysiologic responsesJournal of Allergy and Clinical Immunology, 1998
- Time to Peak Insulin Level, Relative Bioavailability, and Effect of Site of Deposition of Nebulized Insulin in Patients with Noninsulin-Dependent Diabetes MellitusJournal of Aerosol Medicine, 1998
- Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction.Thorax, 1996
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994
- Drug delivery to the respiratory tract using dry powder inhalersInternational Journal of Pharmaceutics, 1994